Compare DexCom, Inc. (DXCM) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tripadvisor Inc Common Stock — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while Tripadvisor Inc Common Stock trades at $15.05 (market cap $1.70B). The key difference: DexCom, Inc. is far larger — about 16.5× Tripadvisor Inc Common Stock's market cap. Which is the better fit depends on your goals.
| DXCM | TRIP | |
|---|---|---|
Market Cap | $28.06B | $1.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $19.14 |
52-Week Low | $54.84 | $9.24 |
Enterprise Value | $27.03B | $1.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
TRIP trades at $14.36, up 2.57% today, with a bullish technical signal from moving averages and a neutral RSI near 67. Recent Q2 2026 earnings are pending, following mixed Q1 results. The company's $700 million sale of TheFork to American Express (Reuters, 2026-06-15) provides cash but highlights strategic refocusing. Revenue grew to $1.89 billion in 2025, though net margins are thin at 0.99%, and the P/E ratio of 132.73 suggests high earnings expectations relative to current profits.
Outlook is cautious; analyst consensus is a Hold (60.72%) with a $13.87 price target below current levels, indicating skepticism. Opportunities include leveraging the TheFork sale proceeds for core travel growth, but risks involve competitive pressures and inconsistent earnings. The stock's high valuation requires strong future performance to justify, with macroeconomic factors like inflation posing additional headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
